PPCB: PPCB preclinical PRP shows >90% tumor inhibition and >2.5x survival in pancreatic cancer models

AI Summary

Propanc (PPCB) reported preclinical orthotopic and patient-derived xenograft PDAC data where intravenous PRP (three times weekly) produced >90% mean tumor growth inhibition versus vehicle (p<0.001), markedly reduced liver and peritoneal metastases, remodeled the tumor microenvironment, enhanced sensitivity of chemo‑resistant cells to gemcitabine/nab‑paclitaxel, and extended median overall survival >2.5‑fold versus controls. These are animal xenograft results only; the company is advancing GMP manufacture, PK assay validation, holds FDA Orphan Drug designation for pancreatic cancer, and is preparing a Phase 1b First‑in‑Human study in ~40–45 patients with a clinical trial application expected in the coming months.

Positives

>90% mean tumor growth inhibition in orthotopic and PDX PDAC models (p<0.001)
Greater than 2.5‑fold median overall survival extension in treated animals versus controls
Marked reduction in metastatic burden and remodeling of tumor microenvironment (decreased CAF activity, reduced fibrosis) with increased sensitivity to gemcitabine/nab‑paclitaxel

Negatives

All efficacy data reported are preclinical (animal xenograft models); no human efficacy data yet
Release does not disclose animal sample sizes or full study design details
PRP is at an earlier stage versus clinical RAS(ON) inhibitors that have reported Phase 3 human results